scholarly journals The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population

2018 ◽  
Vol 143 (1) ◽  
pp. 184-189 ◽  
Author(s):  
Bo Lan ◽  
Fei Ma ◽  
Xiaoyu Zhai ◽  
Qiao Li ◽  
Shanshan Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Chinese Han Population ◽  
Breast Cancer Patients ◽  
Chinese Han ◽  
Han Population ◽  
Tamoxifen Efficacy ◽  
The Relationship ◽  
Cyp2d6 Polymorphisms

scholarly journals Lack of Association between rs2067474 Polymorphism in Histamine Receptor H2Gene and Breast Cancer in Chinese Han Population

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Wen-Ke Cai ◽  
Jia-Bin Zhang ◽  
Niu-Min Wang ◽  
Ying-Lin Wang ◽  
Can-Hu Zhao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Cancer Patients ◽  
Chinese Han Population ◽  
Clinicopathological Parameters ◽  
Breast Cancer Patients ◽  
Chinese Han ◽  
Enhancer Element ◽  
Han Population

Histamine H2receptor (HRH2) was previously suggested to affect the proliferation of breast cancer cells and disease-free survival of breast cancer patients. Furthermore, a common polymorphism, rs2067474, was identified in an enhancer element of theHRH2gene promoter and was reported to be associated with various diseases including cancer. However, the relationship between this polymorphism and breast cancer risk and malignant degree remains unclear. The aim of this study was to clarify the clinical association of rs2067474 polymorphism with breast cancer. A total of 201 unrelated Chinese Han breast cancer patients and 238 ethnicity-matched health controls were recruited and rs2067474 polymorphism was genotyped. Logistic regression analyses were performed to calculate the odds ratios (ORs) as a measure of association of genotype with breast cancer according to 3 genetic models (dominant, recessive, and additive). Although the percentage of hormone receptor negative cases tended to be higher in AA genotypes, we did not find any significant associations of rs2067474 polymorphism with breast cancer risk or with related clinicopathological parameters in the present study, which indicates that rs2067474 polymorphism ofHRH2gene might not be a risk factor in the development of breast cancer in Chinese Han population.

scholarly journals Research on the Relationship Between Self-Management Efficacy and Quality of Life for Breast Cancer Patients Receiving Endocrine Therapy

2022 ◽  
Author(s):  
Hongjie Yi ◽  
Haoran Jiang ◽  
Aiping Wang ◽  
Wei Zong ◽  
Yu Dong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Influencing Factors ◽  
The Self ◽  
Self Management ◽  
Breast Cancer Patients ◽  
The Relationship

Abstract Purpose To investigate the status quo and relationship between self-management efficacy and quality of life (QOL) of patients with breast cancer undergoing endocrine therapy, and to explore the influencing factors of QOL. Methods The convenience sampling method was used to select 240 patients who received endocrine therapy after breast cancer surgery in the First Hospital of China Medical University, the self-designed general data questionnaire, self-management efficacy questionnaire for breast cancer patients with endocrine therapy and quality of life scale for breast cancer patients were used to investigate. The frequency, percentage, mean ± standard deviation were used to describe patients' self-management efficacy and quality of life. Pearson correlation analysis was used to analyze the relationship between self-management efficacy and quality of life, and univariate analysis and multiple stepwise regression were used to analyze the influencing factors of QOL. Results The scores of self-management efficacy and QOL of patients with breast cancer endocrine therapy were 125.21 ± 25.57 and 153.33 ± 19.31 respectively, which were at the middle level; self-management efficacy was significantly positively correlated with quality of life ( p < 0.01 ) ; multiple stepwise regression results showed that self-management efficacy, the number of physical symptoms, monthly family income and recurrence and metastasis were the influencing factors of QOL. Conclusion The self-management efficacy of endocrine therapy was positively correlated with QOL in breast cancer patients. The higher the self-management efficacy of endocrine therapy, the better QOL in breast cancer patients. Self-management efficacy is the main factor affecting the quality of life of breast cancer patients undergoing endocrine therapy. Improving the level of self-management efficacy can improve their quality of life.

scholarly journals The relationship between human muth homolog 1 gene mutation at site 415 and sporadic colon cancers in Chinese Han population

2010 ◽  
Vol 4 (6) ◽  
pp. 923-930
Author(s):  
Weiping Tao ◽  
Sheng Hu ◽  
Zhiwei Wang ◽  
Jian Fan
Keyword(s):  
Colon Cancer ◽  
Cancer Patients ◽  
Chinese Han Population ◽  
Normal Colonic Mucosa ◽  
Chinese Han ◽  
Han Population ◽  
Colon Cancers ◽  
Sporadic Colon Cancer ◽  
The Relationship ◽  
Hmlh1 Gene

Abstract Background: The genetic factors of colon cancer play an important role in the tumor development and growth. The incidence of colon cancers has greatly increased in China. However, few data is available for the relationship between human muth homolog 1 (hMLH1) gene mutation at site 415 and sporadic colon cancers in Chinese population. Objective: Investigate the relationship between G→C mutation in hMLH1 gene at site 415 and sporadic colon cancers in Chinese Han population. Methods: Using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and DNA sequencing techniques, the genotype of the hMLH1 gene was analyzed at site 415 in 97 cases of sporadic colon cancer patients and 138 controls. Reverse-transcription (RT)-PCR was used to determine the level of hMLH1 mRNA expression in normal colonic mucosa of patients with different genotype. Results: The frequency of genotype C/C at the 415 site of the hMLH1 gene was significantly higher in colon cancer patients than in controls. The expression levels of hMLH1 mRNA in normal colonic mucosa were similar in colon cancer patients with different genotypes. Conclusion: G’!C mutation in hMLH1 gene at site 415 may represent a genetic factor that is associated with sporadic colon cancer in a small group of Chinese Han population.

Role of Polymorphisms of FAM13A, PHLDB1, and CYP24A1 in Breast Cancer Risk

2019 ◽  
Vol 19 (8) ◽  
pp. 579-588 ◽  
Author(s):  
Ying Wei ◽  
Xiaolin Wang ◽  
Zhe Zhang ◽  
Mingrui Xie ◽  
Yuyao Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Cancer Susceptibility ◽  
Recessive Model ◽  
Chinese Han Population ◽  
Breast Cancer Patients ◽  
Chinese Han ◽  
Han Population ◽  
Increased Risk

Background: Single-nucleotide polymorphisms (SNPs) are important indicators of susceptibility to breast cancer. Objective: To assess the associations between SNPs in the FAM13A, PHLDB1, and CYP24A1 gene and breast cancer risk in the Chinese Han population. Methods: We performed a case-control study including 379 female breast cancer patients and 407 female healthy controls. The three SNPs were genotyped using Agena MassARRAY platform. The χ2 test was used to compare alleles and genotypes frequencies of polymorphisms between case and control groups. Genetic models analyses to assess the associations between SNPs and breast cancer risk by computing odds ratios (ORs) and 95% confidence intervals (CIs) using logistic regression. RegulomeDB and HaploReg databases were used to calculate possible functional effects of polymorphisms. Results: Overall analysis results showed that rs4809957 was associated with an increased risk of breast cancer (allele A: OR = 1.27, 95% CI: 1.03-1.55, p = 0.024; AA vs. GG: OR = 1.80, 95% CI: 1.15–2.82, p = 0.010; recessive model: OR = 1.70, 95% CI: 1.12–2.58, p = 0.012); and rs1059122 was found to be associated with a reduced breast cancer risk in the recessive model (OR = 0.71, 95% CI: 0.51–0.98, p = 0.039). Stratification analysis found significant associations between the three SNPs (rs1059122, rs17748, and rs4809957) and breast cancer risk. Conclusion: Our results suggested that rs1059122 (FAM13A), rs17748 (PHLDB1), and rs4809957 (CYP24A1) might contribute to breast cancer susceptibility in the Chinese Han population. Future studies with large samples are required to confirm our findings, as well as functional studies are needed to explore their function in the breast cancer development.

scholarly journals rs12537 Is a Novel Susceptibility SNP Associated With Estrogen Receptor Positive Breast Cancer in Chinese Han Population

2021 ◽  
Vol 8 ◽  
Author(s):  
Jingkai Xu ◽  
Guozheng Li ◽  
Mengyun Chen ◽  
Wenjing Li ◽  
Yaxing Wu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Menopausal Status ◽  
Susceptibility Gene ◽  
Chinese Han Population ◽  
Breast Cancer Patients ◽  
Chinese Han ◽  
Han Population ◽  
Risk Estimates ◽  
Er Positive ◽  
Positive Breast Cancer

Genetic testing is widely used in breast cancer and has identified a lot of susceptibility genes and single nucleotide polymorphisms (SNPs). However, for many SNPs, evidence of an association with breast cancer is weak, underlying risk estimates are imprecise, and reliable subtype-specific risk estimates are not in place. A recent genome-wide long non-coding RNA (lncRNA) association study in Chinese Han has verified a genetic association between rs12537 and breast cancer. This study is aimed at investigating the association between rs12537 and the phenotype. We collected the clinical information of 5,634 breast cancer patients and 6,308 healthy controls in the early study. And χ2 test was used for the comparison between different groups in genotype. The frequency of genotypic distribution among SNP rs12537 has no statistically significant correlation with family history (p = 0.8945), menopausal status (p = 0.3245) or HER-2 (p = 0.2987), but it is statistically and significantly correlated with ER (p = 0.004006) and PR (p = 0.01379). Most importantly, compared to the healthy control, rs12537 variant is significantly correlated with ER positive patients and the p-value has reached the level of the whole genome (p = 1.66E-08 &lt;5.00E-08). Furthermore, we found rs12537 associated gene MTMR3 was lower expressed in breast cancer tissues but highly methylated. In conclusion, our findings indicate that rs12537 is a novel susceptibility gene in ER positive breast cancer in Chinese Han population and it may influence the methylation of MTMR3.

scholarly journals MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Sanne Løkkegaard ◽  
Daniel Elias ◽  
Carla L. Alves ◽  
Martin V. Bennetzen ◽  
Anne-Vibeke Lænkholm ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Cycle ◽  
Cancer Patients ◽  
Endocrine Therapy ◽  
Endocrine Resistance ◽  
Predictive Marker ◽  
Endocrine Treatment ◽  
Breast Cancer Patients ◽  
Minichromosome Maintenance ◽  
Primary Tumors

AbstractResistance to endocrine therapy in estrogen receptor-positive (ER+) breast cancer is a major clinical problem with poorly understood mechanisms. There is an unmet need for prognostic and predictive biomarkers to allow appropriate therapeutic targeting. We evaluated the mechanism by which minichromosome maintenance protein 3 (MCM3) influences endocrine resistance and its predictive/prognostic potential in ER+ breast cancer. We discovered that ER+ breast cancer cells survive tamoxifen and letrozole treatments through upregulation of minichromosome maintenance proteins (MCMs), including MCM3, which are key molecules in the cell cycle and DNA replication. Lowering MCM3 expression in endocrine-resistant cells restored drug sensitivity and altered phosphorylation of cell cycle regulators, including p53(Ser315,33), CHK1(Ser317), and cdc25b(Ser323), suggesting that the interaction of MCM3 with cell cycle proteins is an important mechanism of overcoming replicative stress and anti-proliferative effects of endocrine treatments. Interestingly, the MCM3 levels did not affect the efficacy of growth inhibitory by CDK4/6 inhibitors. Evaluation of MCM3 levels in primary tumors from four independent cohorts of breast cancer patients receiving adjuvant tamoxifen mono-therapy or no adjuvant treatment, including the Stockholm tamoxifen (STO-3) trial, showed MCM3 to be an independent prognostic marker adding information beyond Ki67. In addition, MCM3 was shown to be a predictive marker of response to endocrine treatment. Our study reveals a coordinated signaling network centered around MCM3 that limits response to endocrine therapy in ER+ breast cancer and identifies MCM3 as a clinically useful prognostic and predictive biomarker that allows personalized treatment of ER+ breast cancer patients.

The relationship of self-acceptance with decision making duration in cancer patient to perform mastectomy

2021 ◽  
pp. 1-5
Author(s):  
Ayu Ratuati Setiawan ◽  
Feny Tunjungsari ◽  
Mochamad Aleq Sander
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Cross Sectional ◽  
Abnormal Growth ◽  
Self Acceptance ◽  
Observation Method ◽  
Relationship Of ◽  
The Relationship

BACKGROUND: Cancer is a disease caused by abnormal growth of body cells that turn malignant and continue to grow uncontrollably. One of the treatments for breast cancer is mastectomy. The quickness of decision-making determines the survival rate of prognosis patients. OBJECTIVE: This study aimed to determine the relationship of self-acceptance with decision-making duration in cancer patients to perform a mastectomy. METHODS: An analytic observation method with cross-sectional design. The samples were taken by purposive sampling method with 50 samples of breast cancer patients. Data collected include age, last level of education, marital status, profession, stage of cancer during mastectomy, self-acceptance score, and decision-making duration to perform a mastectomy. RESULTS: The data analyzed with the Kruskal–Wallis test. The test showed the relationship of self-acceptance (p = 0.027) with decision-making duration in breast cancer patients to perform a mastectomy. CONCLUSION: In Conclusion, there is a relationship of self-acceptance with decision-making duration in breast cancer patients to perform a mastectomy.

Sign in / Sign up

Export Citation Format

Share Document